Efficacy and Safety of Fexuprazan in Patients with Acute or Chronic Gastritis

Background/Aims@#Fexuprazan is a novel potassium-competitive acid blocker that could be of benefit to patients with gastric mucosal injury. The aim of this study was to assess the 2-week efficacy and safety of fexuprazan in patients with acute or chronic gastritis. @*Methods@#In this study, 327 patients with acute or chronic gastritis who had one or more gastric erosions on endoscopy and subjective symptoms were randomized into three groups receiving fexuprazan 20 mg once a day (q.d.), fexuprazan 10 mg twice a day (b.i.d.), or placebo for 2 weeks. The posttreatment assessments were the primary endpoint (erosion improvement rate), secondary endpoints (cure rates of erosion and edema and improvement rates of redness, hemorrhage, and subjective symptoms), and drug-related adverse events. @*Results@#Among the patients, 57.8% (59/102), 65.7% (67/102), and 40.6% (39/96) showed erosion improvement 2 weeks after receiving fexuprazan 20 mg q.d., fexuprazan 10 mg b.i.d., and placebo, respectively. Both fexuprazan 20 mg q.d. and 10 mg b.i.d. showed superior efficacy to the placebo (p=0.017 and p<0.001, respectively). Likewise, both fexuprazan 20 mg q.d. and 10 mg b.i.d. also showed higher erosion healing rates than the placebo (p=0.033 and p=0.010, respectively). No difference was noted in the edema healing rate and the improvement rates for redness, hemorrhage, and subjective symptoms between the fexuprazan and placebo groups.No significant difference was noted in the incidence of adverse drug reactions. @*Conclusions@#Fexuprazan 20 mg q.d. and 10 mg b.i.d. for 2 weeks showed therapeutic efficacy superior to that of placebo in patients with acute or chronic gastritis (ClinicalTrials.gov identifier NCT04341454).

A rare case of epiphyseal chondromyxoid fibroma of the proximal tibia.

Chondromyxoid fibroma is an uncommon benign cartilaginous tumor of the bone. It occurs most frequently in the metaphysis of long tubular bones, and an epiphyseal location is exceedingly rare. We present here an unusual case of a chondromyxoid fibroma that occurred in the epiphysis of the proximal tibia with an open growth plate. MR imaging findings of this tumor, which has, to the best of our knowledge, never been described in an epiphyseal location, makes the present case unique.

Dynamic sonography of external snapping hip syndrome.

OBJECTIVE: To evaluate the dynamic sonographic findings of external snapping hip syndrome. METHODS: Five patients with 7 cases of painful external snapping hip (3 male and 2 female; age range, 14-32 years; mean, 19 years) were examined with sonography. Two patients had bilateral snapping. Dynamic sonographic examinations of hips were performed with a linear 5- to 12-MHz transducer during hip motion. RESULTS: Dynamic sonographic studies of the affected hip revealed causes of the external snapping hip in all cases. It was elicited by an abnormal jerky movement of the iliotibial band overlying the greater trochanter in 5 of 7 cases and of the gluteus maximus muscle in 2 cases. The iliotibial band over the greater trochanter was hypoechoic in 3 of the 5 cases and thickened in 1 case. Dynamic sonography showed good correlations between the jerky movements of the iliotibial band and the gluteus maximus muscle and the painful snapping reported by the patients. CONCLUSIONS: Dynamic sonography was helpful in the diagnosis of external snapping hip syndrome; it showed real-time images of sudden abnormal displacement of the iliotibial band or the gluteus maximus muscle overlying the greater trochanter as a painful snap during hip motion.